Pre-Made Alefacept Biosimilar, Fusion Protein targeting CD2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting LFA-2/SRBC/T11 for drug discovery and mechanism of action (MOA) research

Pre-Made Alefacept Biosimilar, Fusion Protein targeting CD2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting LFA-2/SRBC/T11 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Alefacept is a genetically engineered immunosuppressive drug. It was sold under the brand name Amevive in Canada, the United States, Israel, Switzerland and Australia. In 211, the manufacturers made a decision to cease promotion, manufacturing, distribution and sales of Amevive during a supply disruption. According to Astellas Pharma US, Inc.,[1] the decision to cease Amevive sales was neither the result of any specific safety concern nor the result of any FDA-mandated or voluntary product recall. On the other hand, usage of Amevive was associated with a certain risk of development systemic diseases such as malignancies. This drug was never approved for the European drug market.

Alefacept is a recombinant Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Alefacept is used to treat moderate to severe plaque psoriasis. It Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen.